RESOLUTE SCIENCE, INC.
RS-5, a small-molecule therapeutic that targets tumor-associated macrophages (TAMs) to deliver anti-cancer agents to soft tissue sarcomas
- Sector
- Biotech
- Headquarters
- Rancho Santa Fe, CA
- Founded
- 2020
- Latest Form D
- $1.4M, Feb 2025
- Total capital
- $3.7M
- Federal grants
- $2.1M
- 3 awards · 2023–2025
- Rank in peer group#1 of 326
- Private capital raised
- $1.6M
- 2 Form D · last Feb 2025
- 20 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 12 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Targeting Macrophages to Treat Soft Tissue Sarcomas$998K
- Private capital raisedForm D · SEC · 2nd filing$1.4M
- Federal grantHealth and Human S · Phase II · Targeting Macrophages to Treat Soft Tissue Sarcomas$727K
- Private capital raisedForm D · SEC · 1st filing$250K
- Federal grantHealth and Human S · Phase I · Targeting Macrophages to Treat Soft Tissue Sarcomas$399K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
9months
from RESOLUTE SCIENCE, INC.’s first federal award to its first private round.
- First federal award · Aug 2023
- Health and Human S · $399K
- First Form D · May 2024
- $250K · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#1 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Faith BarnettResearcherExecutive Officer, DirectorLinked by $2.1M in grants as PI
- Andre BasbaumExecutive Officer, DirectorNamed in SEC Form D filings
- James MackayDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 12- PendingCompositions And Methods For Targeting Tumor-associated MacrophagesUSPTOApplication 19157578
- PendingCompositions And Methods For Targeting Tumor-associated MacrophagesUSPTOApplication 19157584
- PendingCompositions And Methods For Targeting Tumor-associated MacrophagesUSPTOApplication PCTUS2024016748
Show all 12 patent records
- Compositions And Methods For Targeting Tumor-associated MacrophagesApplication 19157578Pending
- Compositions And Methods For Targeting Tumor-associated MacrophagesApplication 19157584Pending
- Compositions And Methods For Targeting Tumor-associated MacrophagesApplication PCTUS2024016748Pending
- Compositions And Methods For Targeting Tumor-associated MacrophagesApplication PCTUS2024016750Pending
- Compositions And Methods For Targeting Tumor-associated MacrophagesApplication PCTUS2024016745Pending
- Compositions And Methods For Targeting Tumor-associated MacrophagesApplication PCTUS2024016752Pending
- Compositions And Methods For Targeting Tumor-associated MacrophagesApplication 63447626Pending
- Compositions And Methods For Targeting Tumor-associated MacrophagesApplication 63447628Pending
- Compositions And Methods For Targeting Tumor-associated MacrophagesApplication 63447627Pending
- Compositions And Methods For Targeting Tumor-associated MacrophagesApplication 63447629Pending
- Compositions And Methods For Targeting Tumor-associated MacrophagesApplication 19157577Pending
- Compositions And Methods For Targeting Tumor-associated MacrophagesApplication 19157572Pending
Related companies, and why
- 4E THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Hillhurst Biopharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Agilvax, Inc.Similar federal contract value in Biotech · null in contracts
- ZYWIE LLCSimilar federal contract value in Biotech · null in contracts
- ORPRO THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- BIOLYTX PHARMACEUTICALS CORPSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .